SkyQuest Technology Group recently introduced Influenza Vaccine Market study with in-depth overview, describing about the Product/Industry Scope and elaborates market outlook and status (2025-2032). The market Study is segmented by key regions which is accelerating the marketization. The Influenza Vaccine Market has witnessed Excellent growth over the past decade and is expected to maintain its upward trajectory.
Influenza Vaccine Market size was valued at USD 7.91 Billion in 2023 and is poised to grow from USD 8.46 Billion in 2024 to USD 14.52 Billion by 2032, growing at a CAGR of 6.98% during the forecast period (2025-2032).
The influenza virus circulates continue indefinitely, causing regional epidemics and outbreaks that have resulted in thousands of deaths. For instance, according to data from the Centers for Disease Control and Prevention (CDC), more than 13 million flu cases have been recorded in the 2019-20 timeframe. The changing nature of the virus necessitates an annual change in the vaccine strain to match the influenza virus strain around the world. During the forecasted period, the increasing prevalence of influenza epidemics and seasonal outbreaks is expected to boost product sales.
Get a Free Sample PDF of the Report – https://www.skyquestt.com/sample-request/Influenza-vaccine-market
The 2025 Influenza Vaccine Market report provides a comprehensive analysis of key industry players, market trends, pricing structures, and competitive dynamics, offering insights into the market landscape from 2025 to 2032. As a rapidly evolving sector, the Influenza Vaccine Market drives economic growth, innovation, and technological advancements through the development, production, and distribution of products and services. This report highlights the market’s growth potential and its impact on industries, providing valuable insights for stakeholders, investors, and policymakers.
Detailed Segmentation and Classification of the report (Market Size and Forecast – 2032, Y-o-Y growth rate, and CAGR):
The Influenza Vaccine Market can be segmented based on several factors, including product type, application, end-user, and distribution channel.
Type
Inactivated, and Live Attenuated
Indication
Quadrivalent, Trivalent
Route of administration
Injection, and Nasal Spray
Age group
Pediatric, and Adult
Distribution Channel
Hospital & Pharmacies, Government & Institutional Supply, Others
Influenza Vaccine Market – Regional Analysis:
– Influenza Vaccine North America Market includes (Canada, Mexico, USA)
– Influenza Vaccine Europe Market includes (Germany, France, Great Britain, Italy, Spain, Russia)
– Influenza Vaccine Asia-Pacific Market includes (China, Japan, India, South Korea, Australia)
– Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa)
– Influenza Vaccine South America Market includes (Brazil, Argentina)
– Influenza Vaccine Oceania Market (Australia & New Zealand)
Top Market Players in Influenza Vaccine Market are:
GSK plc (U.K.)
Pfizer Inc. (U.S.)
Vaxess Technologies Inc. (U.S.)
Merck & Co., Inc. (U.S.)
Viatris Inc. (U.S.)
OSIVAX (France)
AstraZeneca (U.K.)
SINOVAC (China)
CSL Limited (Australia)
Emergent BioSolutions Inc. (U.S.)
Emergex Vaccines (U.K.)
Sanofi (France)
BIKEN Co., Ltd. (Japan)
Abbott (U.S.)
Altimmune Inc. (U.S.)
Baxter International Inc. (U.S.)
BioDiem Ltd (Australia)
BiondVax Pharmaceuticals Ltd. (Israel)
F. Hoffmann-La Roche Ltd. (Switzerland)
FluGen Inc. (U.S.)
Mitsubishi Chemical Group Corp. (Japan)
Novavax Inc. (U.S.)
Otsuka Holdings Co. Ltd. (Japan)
Shijiazhuang Yiling Pharmaceutical Co., Ltd. (China)
Influenza Vaccine Key Market Trends:
The coronavirus pandemic had an unforeseen impact on routine immunization programmes and campaigns in both developing and developed countries. However, flu vaccination rates have increased significantly during the pandemic due to factors such as increased pressure from health experts/health departments, as well as the extension/expansion of various government programmes that provide free flu vaccination.
Furthermore, growing public awareness about the increased risk of getting infected with COVID-19 if the flu weakens the immune system is another factor contributing to flu vaccine uptake. For instance, the Centers for Disease Control and Prevention (CDC) reported that as of May, over 189.4 million flu vaccines for the 2020-2021 flu season had been distributed in the United States, compared to 174 million in the 2019-2020 season. In addition, according to the most recent study published in 2020, researchers in Brazil stated that a flu shot could reduce mortality rates by 20% when administrated prior to initiation of COVID-19 and by approximately 27% when administered after the onset of COVID-19. As a result, the above- mentioned factors are likely to drive demand over the forecast year.
The increasing prevalence of influenza disease around the world has prompted governments to implement various strategies to increase flu vaccine uptake in their respective countries. One of the most important strategies in the inclusion of the vaccine in the immunization programmes of countries focusing on emerging and low-income economies. Nowadays, increased public awareness of infectious diseases has resulted in more timely vaccinations in developing countries. Developing countries have revised their immunization programes and made flu vaccination mandatory for all age groups.
Also Read –
Forward-Looking Insights
The Influenza Vaccine Market is set to experience sustained growth, fueled by technological advancements, broader market access, and rising industry demand. With the industry addressing emerging challenges and capitalizing on new opportunities, it is expected to drive innovation and play a pivotal role in advancing health and economic progress.
About Company:
SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.
We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization have expanded our reach across North America, Europe, ASEAN and Asia Pacific.
Contact Details:
SkyQuest Technology Group
USA (+1) 351-333-4748
Email: [email protected]




